EGFR
All Product Categories
-
EGFR Inhibitors
(581)
View all products
-
EGFR Agonist
(1)
View all products
-
EGFR Antagonist
(1)
View all products
-
EGFR Activators
(5)
View all products
-
EGFR Modulators
(6)
View all products
-
EGFR Chemicals
(3)
View all products
-
EGFR Inducers
(4)
View all products
-
EGFR Degraders
(22)
View all products
-
EGFR Controls
(6)
View all products
-
EGFR Substrate
(1)
View all products
-
EGFR Ligands
(13)
View all products
-
EGFR Related Products (757)
Related Products (757)
-
EGFR/HER2-IN-8
0 ImagesCat. No.: HY-151161CAS No.: 2820126-32-5EGFR/HER2-IN-8 (compound 34) is a EGFR/HER2 and DHFR inhibitor. EGFR/HER2-IN-8 inhibits EGFR kinase, HER2 kinase and DHFR with IC50s of 0.45, 0.244 and 5.669 μM, respectively. EGFR/HER2-IN-8 shows anticancer activity against several cancer cell lines with high safety profile and selectivity indices. EGFR/HER2-IN-8 can be used for the research of cancer.
-
Becotatug (powder)
0 ImagesCat. No.: HY-P990049ASynonyms: JMT-101 (powder); MRG003 Antibody (powder)Becotatug (powder) (JMT-101) is a humanized IgG1 monoclonal antibody targeting epidermal growth factor receptor (EGFR), and serves as the antibody component of the antibody-drug conjugate Becotatug vedotin (HY-171265). Becotatug (powder) specifically binds to the extracellular domain of EGFR, induces receptor internalization and degradation, blocks the EGFR signaling pathway, and mediates antibody-dependent cellular cytotoxicity. When conjugated to monomethyl auristatin E (MMAE) (HY-15162) via a valine-citrulline cleavable linker, Becotatug (powder) enables targeted delivery of cytotoxic drugs to EGFR-positive tumor cells. Becotatug (powder) can be used for research related to non-small cell lung cancer, nasopharyngeal carcinoma, and head and neck squamous cell carcinoma.
-
Lifirafenib maleate
0 ImagesCat. No.: HY-18957BCAS No.: 1854985-74-2Synonyms: BGB-283 maleateLifirafenib (BGB-283) maleate is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.
-
EGFR-IN-176
0 ImagesCat. No.: HY-178057CAS No.: 2754394-10-8EGFR-IN-176 is an orally active and ATP-competitive EGFR mutant inhibitor (particularly C797S-mediated EGFR triple mutant). EGFR-IN-176 effectively inhibits subsequent AKT signaling and induces apoptosis in Ba/F3 and PC-9 cells expressing EGFR19del/T790M/C797S and EGFRL858R/T790M/C797S. EGFR-IN-176 selectively inhibits EGFR signaling in cell lines harboring EGFR triple mutation and shows no inhibitory effect against A431 cells that express wild-type EGFR. EGFR-IN-176 can effectively inhibit the enzymatic activity of ALK (IC50 < 0.5 nM). EGFR-IN-176 can be used for the study of non-small cell lung cancer (NSCLC).
-
EGFR-IN-191
0 ImagesCat. No.: HY-181093EGFR-IN-191 is an anti-tumor agent targeting both EGFR and AKT. EGFR-IN-191 exerts its anti-tumor activity by inducing DNA damage, apoptosis, cell cycle arrest, and inhibition of the PI3K/AKT-EGFR signaling pathway in tumor cells. EGFR-IN-191 can be used in the study of tumors such as triple-negative breast cancer.
-
EGFR G719S Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70705EGFR is a driver of tumorigenesis. EGFR is mainly found in an auto-inhibited, dimerization-incompetent, state at the plasma membrane (PM). Ligand binding promotes receptor dimerization, which determines a series of structural rearrangements that are conveyed to the cytoplasmic domain allowing the formation of asymmetric dimers between the two juxtaposed catalytic domains. EGFR has multiple mutants. EGFR G719S Recombinant Human Active Protein Kinase is a recombinant EGFR G719S protein that can be used to study EGFR G719S-related functions.
-
Erbicin
0 ImagesCat. No.: HY-P991979Erbicin is a single-chain antibody against the human ErbB2 receptor. Erbicin specifically binds to ErbB2-positive cells, inhibits receptor autophosphorylation, and is internalized by target cells. Erbicin can be used in breast cancer-related research.
-
MTX-241F
0 ImagesCat. No.: HY-149556CAS No.: 3036637-30-3MTX-241F is a selective small molecule inhibitor targeting EGFR and PI3 kinase family members. MTX-241F is able to penetrate the blood-brain barrier and control tumor growth over the long term. MTX-241F exhibits radiosensitizing activity in patient-derived DIPG neurospheres and may be used in the study of diffuse intrinsic pontine glioma (DIPG).
-
MM-111
0 ImagesCat. No.: HY-P991524CAS No.: 1361108-53-3MM-111 is a bispecific antibody fusion protein targeting the ErbB2/ErbB3 oncogenic unit. MM-111 blocks activation of the PI3K pro-survival pathway. MM-111 binds to the ErbB2 receptor, which localizes the bispecific molecule to ErbB2 over-expressing tumor cells and promotes binding of the anti-ErbB3 arm to the ErbB3 receptor. MM-111 binding to ErbB3 results in inhibition of ErbB3 signaling by blocking the binding of the ErbB3 physiological ligand heregulin. MM-111 can be used for the study of ErbB2 over-expressing breast tumors.
-
Daphnetin (Standard)
0 ImagesDaphnetin (Standard) is the analytical standard of Daphnetin. This product is intended for research and analytical applications. Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC50s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1 , ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research.
-
EGFR-IN-218
0 ImagesCat. No.: HY-189291CAS No.: 2410789-80-7EGFR-IN-218 is an orally effective EGFR inhibitor with IC50 values of 3.85, 0.40, and 140.5 nM against EGFRWT, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively. EGFR-IN-218 inhibits EGFR phosphorylation and downstream ERK1/2 signaling, and exhibits in vivo antitumor activity. EGFR-IN-218 can be used for research on EGFR-mutant non-small cell lung cancer, glioblastoma, and brain metastasis.
-
Masoprocol tetrapivalate
0 ImagesCat. No.: HY-182264CAS No.: 180634-64-4Synonyms: Nordihydroguaiaretic acid tetrapivalateMasoprocol tetrapivalate (Nordihydroguaiaretic acid tetrapivalate) is a catecholic butane metabolite and also a tyrosine kinase activity inhibitor of IGF-1R and EGFR. Masoprocol tetrapivalate regulates tyrosine kinase signaling pathways associated with cell proliferation. Masoprocol tetrapivalate can be used in the research of proliferative diseases, including malignant, precancerous or benign cancers, and solid tumors.
-
EGFR/HER2/CDK9-IN-2
0 ImagesCat. No.: HY-147797CAS No.: 1180924-34-8
-
EGFR-IN-172
0 ImagesCat. No.: HY-175837CAS No.: 878416-74-1EGFR-IN-172 is a EGFR inhibitor. EGFR-IN-172 effectively inhibits the proliferation of non-small cell lung cancer (NSCLC) cells carrying the L858R, T790M and C797S drug-resistant mutations. EGFR-IN-172 inhibits EGFR phosphorylation, induces cell cycle arrest and apoptosis. EGFR-IN-172 can be used for the study of NSCLC.
-
PKM2/PDK1-IN-1
0 ImagesCat. No.: HY-149275CAS No.: 3041957-90-5PKM2/PDK1-IN-1, one of shikonin thioether derivatives, is a dual inhibitor of PKM2/PDK1. PKM2/PDK1-IN-1 inhibits the proliferation of NSCLC cells, and induces apoptosis. PKM2/PDK1-IN-1 induces intercellular ROS production, and regulates the apoptotic proteins, to involves in mitochondrial and death receptor pathway.
